In the latest trading session, 9,050,435 AstraZeneca PLC (NASDAQ:AZN) shares changed hands as the company’s beta touched 0.56. With the company’s most recent per share price at $52.12 changing hands around $0.49 or 0.01% at last look, the market valuation stands at $136.16 Billion. AZN’s current price is a discount, trading about -24.6% off its 52-week high of $64.94. The share price had its 52-week low at $42.84, which suggests the last value was 17.81% up since then. When we look at AstraZeneca PLC’s average trading volume, we note the 10-day average is 7.1 Million shares, with the 3-month average coming to 11.07 Million.
Analysts gave the AstraZeneca PLC (AZN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.5. If we narrow down to specifics, the data shows that 1 out of 26 analysts rate the stock as a Sell, with a further 2 assigning it an Overweight rating. Of the remaining, 3 recommended AZN as a Hold, 20 felt it is a Buy and none rated the stock as Underweight. AstraZeneca PLC’s EPS for the current quarter is expected to be $0.75.
AstraZeneca PLC (NASDAQ:AZN) trade information
Instantly AZN is in green as seen in intraday trades today. With action 0.96%, the performance over the past five days has been green. The jump to weekly highs of $52.23 on Tuesday, Apr 20 added 0.25% to the stock’s daily price. The company’s shares are showing year-to-date upside of 0.04%, with the 5-day performance at 0.06% in the green. However, in the 30-day time frame, AstraZeneca PLC (NASDAQ:AZN) is 0.06% up. Looking at the short shares, we see there were 98.56 Million shares sold at short interest cover period of 8.9 days.
The consensus price target for the stock as assigned by Wall Street analysts is $64.06, meaning bulls need an upside of 22.91% from its recent market value. According to analyst projections, AZN’s forecast low is $47.24 with $83.12 as the target high. To hit the forecast high, the stock’s price needs a +59.48% upsurge from its latest level, while the stock would need to tank -9.36% for it to hit the projected low.
AstraZeneca PLC (AZN) estimates and forecasts
Data shows that the AstraZeneca PLC share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value dive -1.75% over the past 6 months, a 28.86% in annual growth rate that is considerably higher than the industry average of 8.6%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2021 revenue estimates. The rating firms predict current quarter revenue for AstraZeneca PLC will rise +41.5%, while the growth in revenue is estimated to hit 8.3% for the next quarter. Year-over-year growth is forecast to reach 18.2% up from the last financial year.
Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of $7.14 Billion. 3 analysts are of the opinion that AstraZeneca PLC’s revenue for the quarter ending June 01, 2021 will be $7.33 Billion. The company’s revenue for the corresponding quarters a year ago was $6.35 Billion and $6.28 Billion respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 12.4%. The estimates for the next quarter sales put growth at 16.7%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 1.7%. The 2021 estimates are for AstraZeneca PLC earnings to increase by 137.2%, but the outlook for the next 5-year period is at 19.1% per year.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The 2.71% annual yield figure for the share gives it an annual dividend of 1.4. It is important to note, however, that the 2.71% dividend yield ratio should serve as a guide only, as you should also take into consideration many other aspects of a company’s operations and fundamentals before making any investment decision. During the past 5 years, the average dividend yield was 3.7% per year.
AstraZeneca PLC (NASDAQ:AZN)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0% of AstraZeneca PLC shares while 15.68% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 15.68%. There are 900 institutions holding the AstraZeneca PLC stock share, with Primecap Management Company the top institutional holder. As of Dec 30, 2020, the company held 1.91% of the shares, roughly 50.11 Million AZN shares worth $2.5 Billion.
Wellington Management Group, LLP holds the second largest percentage of outstanding shares, with 1.85% or 48.59 Million shares worth $2.43 Billion as of Dec 30, 2020.
Among Mutual Funds, the top two as of Dec 30, 2020 were Vanguard/Primecap Fund and Washington Mutual Investors Fund. With 27042568 shares estimated at $1.35 Billion under it, the former controlled 1.03% of total outstanding shares. On the other hand, Washington Mutual Investors Fund held about 0.78% of the shares, roughly 20.45 Million shares worth around $1.03 Billion.